Pembrolizumab and atezolizumab are monoclonal antibodies approved for cancer immunotherapy targeting immunosuppressive PD-1 and PD-L1 axis used by cancer cells to avoid the host immune system [1]. Despite their efficacy in some types of cancer, they show limited capabilities in the treatment of prostate cancer. However, a combination of monoclonal antibodies with other medications was found to elicit stronger responses. The exact mechanism of such an outcome is unknown [2].
One of the possible factors which may determine treatment effectiveness is the expression of PD-L1 on cancer cells. Herein we assess the expression of PD-L1 in human prostate cell line DU-145 and evaluate atezolizumab binding efficiency to membranous PD-L1 by using flow cytometry approach. Our results show that around 70% of DU-145 cells are PD-L1 positive and atezolizumab in vitro completely saturates membranous PD-L1 at concentrations higher than 0.5 μg/ml indicating that immunotherapy directed towards PD-L1 and PD-1 axis could be effective in prostate cancer.